Nayak Raksha, Pandey Samyak, Kumar Dileep, Kumar Sachindra, Pai K Sreedhara Ranganath
Department of Pharmacology, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, 576104, India.
Department of Pharmaceutical Chemistry, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, 576104, Karnataka, India.
J Ovarian Res. 2025 Aug 14;18(1):185. doi: 10.1186/s13048-025-01770-8.
Epithelial ovarian cancer (EOC), accounting for 90-95% of all ovarian cancer (OC) cases, is the most lethal gynaecological malignancy, primarily due to late-stage diagnosis and the development of chemoresistance. While initial responses to Platinum- and Taxane-based chemotherapy are favorable, nearly 70% of patients relapse within five years. Although signaling pathways such as PI3K/AKT, MAPK, NF-κB, Notch, and Wnt/β-catenin have been individually studied in the context of chemoresistance, recent evidence highlights the importance of dynamic feedback loops and crosstalk among these networks in sustaining the resistant phenotype. Moreover, dysregulated microRNAs (miRNAs), as post-transcriptional regulators, fine-tune these pathways, creating self-sustaining circuits that promote drug efflux, inhibit apoptosis, and maintain cancer stemness. Reciprocal regulation between miRNAs and signaling components establishes robust networks that amplify chemoresistant phenotypes. The review provides a comprehensive overview of the molecular mechanisms driving chemoresistance, emphasising critical elements of signalling pathways and associated miRNAs that contribute to resistance and may function as biomarkers or therapeutic targets to mitigate chemoresistance. To improve clinical outcomes, future research should focus on identifying resistance-associated miRNA signatures and targeting nodal points within miRNA-signaling networks, thereby enabling the development of personalized therapies to overcome drug resistance in EOC.
上皮性卵巢癌(EOC)占所有卵巢癌(OC)病例的90 - 95%,是最致命的妇科恶性肿瘤,主要原因是晚期诊断和化疗耐药的发生。虽然对铂类和紫杉烷类化疗的初始反应良好,但近70%的患者会在五年内复发。尽管PI3K/AKT、MAPK、NF-κB、Notch和Wnt/β-连环蛋白等信号通路已在化疗耐药的背景下分别进行了研究,但最近的证据强调了这些网络之间动态反馈回路和相互作用在维持耐药表型中的重要性。此外,失调的微小RNA(miRNA)作为转录后调节因子,对这些通路进行微调,形成促进药物外排、抑制细胞凋亡并维持癌症干性的自我维持回路。miRNA与信号成分之间的相互调节建立了强大的网络,放大了化疗耐药表型。本综述全面概述了驱动化疗耐药的分子机制,强调了信号通路的关键要素以及相关的miRNA,这些miRNA有助于耐药,可能作为生物标志物或治疗靶点来减轻化疗耐药。为了改善临床结果,未来的研究应专注于识别与耐药相关的miRNA特征,并针对miRNA - 信号网络中的节点,从而开发个性化疗法以克服EOC中的耐药性。